Precio Hua Medicine (Shanghai) Ltd. (HUMDF)

Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 285 full-time employees. The company went IPO on 2018-09-14. The firm is also engaged in the commercialization of HuaTangNing products. The Company’s main product pipeline dorzagliatin or HMS5552 is a glucokinase activator or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The firm mainly conducts its business in the domestic market.